Keros Therapeutics, Inc. (KROS)
| Market Cap | 689.84M |
| Revenue (ttm) | 651,000 |
| Net Income (ttm) | -181.57M |
| Shares Out | 40.51M |
| EPS (ttm) | -5.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,378,035 |
| Open | 16.77 |
| Previous Close | 16.92 |
| Day's Range | 16.62 - 17.64 |
| 52-Week Range | 15.67 - 73.00 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 78.33 (+359.95%) |
| Earnings Date | Nov 6, 2024 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is $78.33, which is an increase of 359.95% from the latest price.
News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share
Keros Therapeutics' stock plummeted due to safety concerns in its Phase 2 TROPOS trial, but the risk-reward profile remains favorable for a rebound. The stock's enterprise value dropped drastically, n...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS...
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
On Thursday, Keros Therapeutics, Inc. KROS voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in combination wit...
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 50 points on Thursday.
Keros Therapeutics halts dosing of blood pressure treatment after safety review
Keros Therapeutics said on Thursday that it has voluntarily halted usage of its 3.0 milligram (mg) and 4.5 mg doses of its high blood pressure treatment in a mid-stage study based on a safety review.
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept wo...
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to f...
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Reports Second Quarter 2024 Financial Results
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Oppenheimer initiated coverage on Keros Therapeutics Inc KROS, a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional sign...
Keros Therapeutics Announces Leadership Updates
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysp...
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ...